ケーススタディ：MacroGenics社、免疫療法の開発におけるバイオマーカー同定のためのトランスレーショナルリサーチ戦略

MacroGenics社は、抗体を用いた革新的ながん治療薬の開発に特化したバイオファーマ企業です。本資料では、Genedata Profiler^®のデータ統合・解析機能を活用し、臨床試験データから新たな洞察を見出して、臨床開発に役立てている例を紹介しています。

Immunotherapy is a revolutionary treatment approach that has witnessed unprecedented bench-to-bedside clinical success . However, this type of therapy is usually effective only in a subset of patients. Further research is crucial to identify predictive biomarkers that optimize the outcome of clinical trials and maximize clinical benefit. 

In this case study, we discuss how MacroGenics, Inc., a biopharmaceutical company specializing in the development of innovative antibody-based therapies for cancer, leverages Genedata Profiler’s data integration and analytics capabilities to maximize the value unlocked from clinical trial data to inform clinical development. 

Who should read it?

Scientific and clinical domain experts seeking to derive biological insights from complex molecular and clinical data to make informed decisions and improve their clinical trial design.